|
发表于 2018-6-9 02:04:44
|
显示全部楼层
36.Chen XL, Murad M, Cui Y-Y, Yao L-J, Venugopal SK, Dawson K, Wu J*. miRNA Signatures in Remaining Liver of 50% Partial Hepatectomy and Small Size Liver Graft in Rat Recipients. Transplantation; 2011: 91:293-299.
37.Schie IW, Wu J, Rutledge JC, Zern MA, Huser T*. Label-free monitoring of lipid droplet formation in living primary hepatocytes after treatment with lipoprotein lipolysis products. J Biophotonics 2011; 4(6):425-34.
38.Lingala S, Cui Y-Y, Chen X, Ruebner BH, Qian X-F, Zern MA, Wu J*. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol 2010; 89:27-35 (PMID: 20511115). The most downloaded paper in the journal, and an image on the face page.
39.Yoon S-J, Kim T-H, Natarajan A, Wang S-S, Choi MS, Wu J*, Zern MA, Senthil K Venugopal. Acute liver injury up-regulates microRNA-491_5p in mice, and its over-expression sensitizes Hep G2 cells for TNF-α-induced apoptosis. Liver Int 2010; 30: 276-287.
40.Venugopal SK, Jiang J, Kim T-H, Li Y, Wang S-S, Torok NJ, Wu J, Zern MA*. Liver fibrosis causes down-regulation of miRNA-150 and miRNA-194 in hepatic stellate cells and their over-expression causes decreased stellate cell activation. Am J Physiol 2010; 298: G101-G106.
41.Tatsukawa H, Fukaya Y, Frampton F, Martinez-Fuentes A, Suzuki K, Kuo K-F, Nagatsuma K, Shimokado K, Okuno M, Wu J, Iismaa S, Matsuura T, Tsukamoto H, Zern MA, Graham R, Kojima S. Role of Transglutaminase 2 in Liver Injury via Crosslinking and Silencing of Transcription Factor, Sp1. Gastroenterology 2009; 136:1783-95 (Impact factor: 12.455).
42.Nyunt T, Dicus CW, Yappert MC, Cui YY, Huser TR, Nantz MH, Wu J*. Physico-Chemical characterization of Poly(Cationic) Lipid and Polylipid Nanoparticles for Liver-Based Gene Delivery. Bioconjugate Chemistry 2009; 20:2047-2054.
43.Wu J*, Hecker JH, Chiamvimonvat N. Antioxidant gene transfer for ischemic diseases. Advanced Drug Delivery Reviews. 2009; 61: 351-363.
44.Kim JW, Wu J*. RNAi, a Powerful Research Tool and Potential Molecular Therapy for Liver Diseases. In Yamada K & Hayashi S Eds: Small Interfering RNA: New Research. ISBN: 978-1-60692-158-6. Nova Science Publishers, Inc. Hauppauge, NY. 2009: 2009: 101-120 (senior author).
45.Ma XC, Duan YY, Catana AM, Jung JJ, Wu J, VandeVoort K, Zern MA*. Differentiation of rhesus monkey embryonic stem cells along hepatocyte lineage. Cloning & Stem Cells 2008; 10:485-94.
46.Liu PG, He SQ, Zhang YH, Wu J*. Protective effects of apocynin and allopurinol on ischemia /reperfusion-induced liver injury in mice. World J Gastroenterol 2008; 14: 2832-2837.
47.Choi MS, Catana AM, Wu J, Borowsky AD, Gambhir SS, Gupta S, Zern MA*. Use of Bioluminescent Imaging to trace the transplantation of immortalized human fetal hepatocytes into mice. Cell Transplant 2008;17: 899-909.
48.Venugopal SK, Wu J, Catana AM, Eisenbud L, He SQ, Duan YY, Bishop C, Follenzi A, Gupta S, Zern MA*. Lentivirus-mediated copper-zinc superoxide dismutase gene delivery protects the liver in mice against oxidative stress. Liver Int 2007; 27: 1311-22.
49.Zhang YH, Venugopal SK, He SQ, Liu PG, Wu J, Zern MA*. The role of novel protein kinase δ and ε isoforms for ethanol-induced apoptosis in primary rat hepatocytes. Cell Signaling 2007; 19:2339-2350.
50.Kim JW, Zhang YH, Zern MA, Rossi JJ, Wu J*. Short Hairpin RNA Causes the Methylation of Transforming Growth Factor-β Receptor II Promoter and Silencing of the Target Gene in Rat Hepatic Stellate Cells. Biochem Biophys Res Commun 2007; 359: 292-297.
51.Qian JM, Zhang H, Wu XF, Chen XP, Wu J*. Improvement of recipient survival after small size graft liver transplantation in rats with pre-ischemic manipulation or administering antisense against NF-κB. Transplant Int 2007; 20: 784-789.
52.Du SL, Pan H, Wang J, Lu WY, Wu J*, Wang JY*. Cyclic RGD Peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther 2007; 322: 560-568 (co-senior author).
53.He SQ, Zhang YH, Venugopal SK, Dicus CW, Perez RV, Ramsamooj R, Nantz MH, Zern MA, Wu J. Delivery of antioxidative enzyme genes protects against ischemia/reperfusion-induced liver injury in mice. Liver Transplant 2006; 12: 1869-1879 (senior author).
54.Yamamoto N, Wu J, Catana A, Cai H,Strom S, Novikoff PM, Zern MA*. An optimal culture condition maintains human hepatocyte phenotype after long term culture. Hepatol Res 2006; 35:169-177.
55.Zhang YH, Gu JF, Zhao LL, He LF, Qian WB, Wang JH, Wang YG, Qian QJ, Qian C, Wu J*, Liu XY*, Complete elimination of colorectal tumor xenograft by combined MnSOD and TRAIL gene-virotherapy. Cancer Research 2006; 66(8): 4291-4298 (co-senior author).
56.Prosser CC, Yen RD, Wu J. Molecular therapy for hepatic injury and fibrosis – where are we? (editorial) World J Gastroenterol 2006, 12: 509-515.
57.Zhan S-S, Jiang XS, Wu J, Halsted C, Zern MA, Torok NJ. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and it is associated with liver fibrosis in vivo. Hepatology 2006; 43: 435-443.
58.Yen DR, Zern MA, Wu J*. Molecular therapy for hepatic fibrosis (invited book chapter). In Frank Columbus Edits: Focus on Chemotherapy Research, Nova Science Publishers, Inc. Hauppauge, NY. 2006:1-23.
59.Wu J. Inhibition of hepatitis viral replication by siRNA. Exp Opin Biol Ther 2004; 4(10): 1649-1659.
60.Duan Y-Y, Wu J, Zhu J-L, Liu S-L, Ozaki I, Strayer DS, Zern MA*. Gene therapy for human alpha 1-antitrypsin deficiency in an animal model using sv40-derived vectors. Gastroenterology 2004; 127: 1222-1232.
61.Wu J*, Liu L, Yen YD, Catana CM, Michael H. Nantz, Zern MA. Liposome-mediated extracellular superoxide dismutase gene delivery protects against acute liver injury in mice. Hepatology 2004; 40: 195-204 (senior author). Impact factor: 11.67
62.Wu J, Zern MA*. Tissue transglutaminase, a key enzyme involved in liver diseases. Hepatology Research 2004; 29: 1-8
63.Shirahashi H, Wu J, Yamamoto N, Wege H, Wager B, Okita K, Zern MA*. Differentiation of human and mouse embryonic stem cells along a hepatocyte lineage. Cell Transplant 2004; 13: 197-211.
64.Wege H, Le HT, Chui MS, Liu L, Wu J, Giri R, Malhi H, Sappal BS, Kumaran V, Gupta S, Zern MA. Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential. Gastroenterology 2003; 124: 432-444. Impact factor: 12.455
65.Liu L, Zern MA, Lizarzburu ME, Nantz MH, Wu J*. Poly(cationic lipid)-mediated in vivo gene delivery to mouse liver. Gene Therapy 2003; 10: 180-187 (senior author).
66.Wu J, Nantz MH, Zern MA*. Targeting hepatocytes for drug and gene delivery---emerging novel approaches and applications. Front Biosci 2002; 7:d717-725 (senior author).
67.Wege H, Wu J, Santos, RM, Zern MA*. Hepatocyte-based therapies for liver diseases: novel strategies and updates. J Port Gastroenterol 2001; 8: 134-142.
68.Wu J, Lizarzaburu ME, Kurth MJ, Liu L, Wege H, Zern MA, Nantz MH. Cationic lipid polymerization as a novel approach for constructing new DNA delivery agents. Bioconjugate Chem 2001; 12: 251-257
69.Wege H, Wu J, Zern MA*. Novel therapeutic modalities for hepatic disease. In: Kiwmu Okita Eds, Frontiers in Hepatology /Liver Cirrhosis. Springer-Verlag Tokyo, Tokyo. 2001:17-29.
70.Di Campli C, Nocente R, Costamagna G, Gentiloni N, Burioni R, Wu J, Armuzz A, Zern MA, Gasbarrini G, Gasbarrini A. No evidence of Helicobacter pylori sequences in pancreatic juices of patients affected by chronic pancreatitis. Int J Pancreatol 2000; 28:181-185.
71.Wu J, Zern MA*. Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 2000; 35: 665-672 (more than 200 citations by 2018).
72.Wu J, Liu SL, Zhu JL, Norton PA, Nojiri S, Hoek J B, Zern MA. Tissue transglutaminase (tTG) functions as a G protein and as a cross-linking molecule in ethanol-induced inhibition of hepatocyte proliferation. J Biol Chem 2000; 275:22213-22219.
73.Wu J, Danielsson Å, Zern MA. Use of isolated hepatocytes in study of xenobiotic hepatotoxicity. In Berry MN & Edwards AM, Eds. Hepatocyte Review, Kluwer Academic Publishers, Dordercht, The Netherlands. 2000: 455-474 (senior author).
74.DiCampli C, Wu J, Zern M.A. Liver targeting approaches for fibrosis. Alcoholism: Clin Exp Res 1999; 23: 950-954.
75.Wu J*, Danielsson Å, Zern MA. Toxicity of hepatotoxins: new insights into mechanisms and therapy. Exp Opin Invest Drugs 1999; 8: 585-607 (senior author). |
|